Our research focuses on inhibiting nucleic acid sensing receptors or signaling pathway molecules to prevent autoantibody production and autoimmune pathology in autoimmune mouse models, in collaboration with the Gantier Group at the Hudson Institute of Medical Research.

We investigate cytokine roles in SLE and opportunities for projects studying their impact on autoreactive B cell survival, focusing on identified genetic variants and therapeutic targets.

We've identified genetic factors contributing to kidney disease in the Australian Indigenous population and are creating mouse models and cell lines to study these genes and test potential treatments.

Our project investigates novel NLRP3 inhibitors to understand their efficacy in human cells and preclinical models of chronic inflammatory diseases.

We utilise a unique mouse model to explore the interaction between genetic predisposition and environmental factors in promoting autoimmune disease development, particularly in SLE research.